Entrada Therapeutics, Inc. Cash Flow Statement
TRDA|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Entrada Therapeutics, Inc. used $42M in operating cash flow and negative free cash flow of $45M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | $65.6M | -$6.7M | -$94.6M |
| Depreciation & Amortization | $3.8M | $2.8M | $1.9M |
| Operating Cash Flow | -$41.6M | $139.8M | -$93.8M |
| Capital Expenditures | $3.2M | $5.6M | $2.9M |
| Free Cash Flow | -$44.7M | $134.2M | -$96.7M |
| FCF Margin | -21.2% | 104.0% | -74.9% |